• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by GlucoTrack Inc.

    10/15/25 4:05:17 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care
    Get the next $GCTK alert in real time by email
    DEFA14A 1 formdefa-14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to §240.14a-12

     

    Glucotrack, Inc.

    (Name of Registrant as Specified in Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.
       
    ☐ Fee paid previously with preliminary materials.
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

    Z:\2025 OPERATIONS\EDGAR\10 OCTOBER\Glucotrack, Inc\10-15-2025\Form DEFA 14A\Draft\Production 

     

    **** IMPORTANT REMINDER TO VOTE YOUR SHARES ****

     

    Dear Glucotrack, Inc. Stockholder:

     

    The Glucotrack, Inc. Special Meeting of Stockholders is scheduled to be held on October 31, 2025. You are receiving this reminder because your votes were not yet processed at the time that it was mailed. If you have already voted, we would like to thank you for your vote.

     

    Even if you plan to attend the Special Meeting, we urge you to vote your shares now, so your vote can be tabulated prior to the meeting.

     

    Your vote is very important. The fastest and easiest way to vote is by telephone or online. Instructions on how to vote your shares by telephone or online are enclosed with this letter. Alternatively, you may sign and return the enclosed voting form in the envelope provided.

     

    Please note that if you own shares of Glucotrack, Inc. stock in multiple accounts, you may receive multiple packages that are not duplicates. Please be sure to vote all your accounts of Glucotrack, Inc. shares.

     

    If you have questions or need help voting your shares, please call our proxy solicitation firm, Sodali & Co., at 1-888-777-2094.

     

    Thank you for your investment in Glucotrack, Inc., and for taking the time to vote your shares.

     

    Sincerely,

     

    Glucotrack, Inc.

     

     

     

    Get the next $GCTK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GCTK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GCTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glucotrack to Participate in the Q3 Virtual Investor Summit

    RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that management will present and participate in one-on-one meetings with investors at the Q3 Virtual Investor Summit, being held on September 16-17, 2025. Presentation detailsPresenter: Paul V. Goode, PhD, President and Chief Executive OfficerDate: Tuesday, September 16, 2025Time: 1:30PM ETWebcast Link: Investor Summit Group Q3 Virtual Conference / GlucotrackInvestor registration: Investor Summit Group About Glucotra

    9/11/25 8:00:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 2025 Strengthened Board of Directors, expands clinical advisory board, and established a Patient Advisory Board Improved capital structure, cash and cash equivalents expected to fund operations through 2025, including initiation of OUS clinical trials and achievement of related milestones Rutherford, NJ, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focu

    8/14/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology

    RUTHERFORD, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that David S. Hirsh, MD, has joined the Company's clinical advisory team as Medical Director – Cardiology, providing strategic leadership for clinical and educational initiatives for the Continuous Blood Glucose Monitor (CBGM). "We are delighted to welcome Dr. Hirsh to the Company in this pivotal role supporting our novel clinical development program," said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. "Dr. Hirsh's expertise in interve

    8/6/25 8:30:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sycoff Drew bought $230,000 worth of shares (182,540 units at $1.26), increasing direct ownership by 7% to 2,951,258 units (SEC Form 4)

    4 - GlucoTrack, Inc. (0001506983) (Issuer)

    4/24/24 6:31:49 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    SEC Filings

    View All

    SEC Form DEFA14A filed by GlucoTrack Inc.

    DEFA14A - Glucotrack, Inc. (0001506983) (Filer)

    10/15/25 4:05:17 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-1/A filed by GlucoTrack Inc.

    S-1/A - Glucotrack, Inc. (0001506983) (Filer)

    10/8/25 5:16:11 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by GlucoTrack Inc.

    DEF 14A - Glucotrack, Inc. (0001506983) (Filer)

    10/3/25 8:18:09 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Carr Brendel Victoria

    3 - Glucotrack, Inc. (0001506983) (Issuer)

    10/7/25 9:57:31 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Director Balo Andrew K was granted 4,692 shares (SEC Form 4)

    4 - Glucotrack, Inc. (0001506983) (Issuer)

    10/7/25 9:38:38 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Director Malave Luis was granted 1,698 shares, increasing direct ownership by 72% to 4,058 units (SEC Form 4)

    4 - Glucotrack, Inc. (0001506983) (Issuer)

    10/7/25 9:06:05 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Leadership Updates

    Live Leadership Updates

    View All

    Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 2025 Strengthened Board of Directors, expands clinical advisory board, and established a Patient Advisory Board Improved capital structure, cash and cash equivalents expected to fund operations through 2025, including initiation of OUS clinical trials and achievement of related milestones Rutherford, NJ, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focu

    8/14/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology

    RUTHERFORD, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that David S. Hirsh, MD, has joined the Company's clinical advisory team as Medical Director – Cardiology, providing strategic leadership for clinical and educational initiatives for the Continuous Blood Glucose Monitor (CBGM). "We are delighted to welcome Dr. Hirsh to the Company in this pivotal role supporting our novel clinical development program," said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. "Dr. Hirsh's expertise in interve

    8/6/25 8:30:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

    RUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, FACE, MACP, has been named as Glucotrack's new Medical Advisory Board member, effective immediately. "With his invaluable experience in diabetes care and his dedication to improving the lives of people with diabetes, Dr. Umpierrez brings exceptional clinical and research expertise that will be instrumental as we advance our novel Continuous Blood Glucose Monitoring (CBGM) technology through clinical development," said Paul V.

    2/26/25 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Financials

    Live finance-specific insights

    View All

    GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT

    1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock (the "Common Stock"), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "GCTK". The new CUSIP number

    5/15/24 4:15:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $GCTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GlucoTrack Inc.

    SC 13G - Glucotrack, Inc. (0001506983) (Subject)

    9/10/24 1:32:03 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by GlucoTrack Inc.

    SC 13G - GlucoTrack, Inc. (0001506983) (Subject)

    1/3/24 1:54:20 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care